Member News
Daicel Arbor Biosciences Expands Leadership and Announces Ravindra Ramadhar as its new President
Ann Arbor, MI (July 1, 2022) – Daicel Arbor Biosciences, a division of Daicel Chiral Technologies, and leader in developing molecular biology research tools, is pleased to introduce Ravindra Ramadhar as its new President. Previously Mr. Ramadhar was Director, Strategy & Business Development within Thermo Fisher Scientific’s Genetics Science Division. Ramadhar brings a vast technical background to Daicel…
Read MoreGrand River Aseptic Manufacturing Invests $160 Million with Award from U.S. Government to Support Continued and Future Growth
Grand River Aseptic Manufacturing (“GRAM”), a leading parenteral contract development and manufacturing organization (CDMO), has signed a multi-year contract with the U.S. Department of Health and Human Services and the U.S. Department of Defense. Under the agreement, GRAM will invest $160 million and receive $120 million from the U.S. government to fund the expansions of…
Read MoreGilbert Foundation invests $18M toward Gene Therapy Initiative
Original Source The Gilbert Family Foundation, a private fund established by Dan and Jennifer Gilbert, announced Thursday it is funding more than $18 million in grants toward a cure for Type 1 neurofibromatosis. The money will fund a three-year campaign as part of the organization’s Gene Therapy Initiative. Four grants totaling $4.4 million will be invested…
Read MoreU.S. Food and Drug Administration Approves Camzyos™ (mavacamten) for the Treatment of Adults With Symptomatic New York Heart Association Class II-III Obstructive Hypertrophic Cardiomyopathy (HCM) to Improve Functional Capacity and Symptoms
Original Source Camzyos is the first and only FDA-approved cardiac myosin inhibitor that specifically targets the source of obstructive HCM Approval based on groundbreaking Phase 3 EXPLORER-HCM trial demonstrating benefit in patients receiving Camzyos versus placebo PRINCETON, N.J.–(BUSINESS WIRE)– Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) approved Camzyos™ (mavacamten, 2.5…
Read MoreVestaron Closes Series C Funding at $82M
May 16, 2022 – (RTP, North Carolina) – Vestaron, a leader in peptide-based biological crop protection, is pleased to announce the official closing of the Series C fundraising efforts at $82M as of May 12, 2022. The financing was significantly oversubscribed with high demand from both existing and new investors. Lead investors joining Vestaron in…
Read MoreMichigan Awarded More Than $236 Million to Support Small Businesses, Create Jobs and Grow Michigan’s Economy
Governor Gretchen Whitmer joined the Michigan Economic Development Corporation (MEDC) to announce that Michigan has been approved for up to $236,990,950 in State Small Business Credit Initiative (SSBCI) funding from the U.S. Department of Treasury. “Ensuring small businesses can thrive and create good-paying jobs in every region of Michigan is critical as we continue growing…
Read MorePhenomics Health Advances Precision Medicine with Products that Integrate Medication Selection, Adherence, Dose Tailoring and Monitoring
Plymouth, MI – May 23, 2022 – Phenomics Health Inc., a bioinformatics-based precision medicine company, today announced the commercial integration of six PrecīsMed® pharmacometabolomic (PMx) and PredictScript™ pharmacogenomic (PGx) clinical products to comprehensively support individual patient medication treatment. Phenomics Health novel product platforms can now provide clinicians with multiple tools to enhance treatment outcomes through…
Read MoreMMS Holdings Selects THREAD as Partner of Choice to Deliver Decentralized Clinical Trials
CANTON, Mich. (05/24/2022) – MMS Holdings Inc. (MMS) – an award-winning, data-focused contract research organization (CRO) – announced a collaboration with THREAD® as its partner of choice for its decentralized clinical trial platform (DCT) and DCT-enabled services. THREAD’s next-generation DCT technology enables faster, more efficient clinical trials while improving access for research participants with higher quality data…
Read MoreCorium Receives FDA Approval of ADLARITY® (donepezil transdermal system) for Treatment of Patients with Alzheimer’s Disease
Original Source Boston, MA, March 14, 2022 – Corium, Inc., a commercial-stage biopharmaceutical company leading the development and commercialization of novel central nervous system (CNS) therapies, announced today the U.S. Food and Drug Administration (FDA) has approved Corium’s ADLARITY (donepezil transdermal system) as a treatment for patients with mild, moderate, or severe dementia of the…
Read MoreSenior Biopharma Executive Joins MMS Holdings as Principal Medical Director
CANTON, Mich. (3/10/2022) – MMS Holdings, a data-focused contract research organization (CRO), announced the addition of Robert Allen, MD, to its team as Principal Medical Director of Global Drug Safety and Pharmacovigilance. Bringing more than 20 years of pharmaceutical industry experience, Dr. Allen has worked at Parke Davis, Pfizer, Adolor, AstraZeneca, Wyeth, Scirex, Premier, and…
Read More